Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Zachary Petersen

Physician Assistant Hill City, SD Physician Assistant

NPI 1568885952 CMS profile 10880936

238 Elm Street, Hill City, SD 57745

Open in the dashboard

General payments

$5,262

307 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zachary Petersen of Hill City, SD is reported in the CMS Open Payments database as having received $5,262 across 307 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $735 39
2024 General $1,087 60
2023 General $908 59
2022 General $1,277 69
2021 General $1,254 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zachary Petersen
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Zachary Petersen were reported at $735. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Zachary Petersen Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,254 $132 $37–$438 $132
2022 $1,277 $155 $48–$522 $149
2023 $908 $167 $52–$557 $160
2024 $1,087 $178 $55–$600 $164
2025 $735 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $870 53 payments
  2. Lilly USA, LLC $652 35 payments
  3. Amgen Inc. $596 37 payments
  4. Novartis Pharmaceuticals Corporation $443 27 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $344 13 payments
  6. Pfizer Inc. $289 17 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $257 15 payments
  8. Sanofi-Aventis U.S. LLC $229 7 payments
  9. Janssen Pharmaceuticals, Inc $212 24 payments
  10. Exact Sciences Corporation $200 11 payments
  11. Other $1,169 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,128 304 payments
  2. Education $134 3 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $713 51 payments
  2. Ozempic $588 50 payments
  3. MOUNJARO $461 23 payments
  4. EVENITY $410 24 payments
  5. Prolia $410 24 payments
  6. Kerendia $344 13 payments
  7. LEQVIO $276 17 payments
  8. SOLIQUA 100/33 $229 7 payments
  9. XARELTO $212 24 payments
  10. COMIRNATY $195 11 payments
  11. Other $3,929 233 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 91 drugs

Part D claims

3,448

Median for Physician Assistant: 241

Drug cost

$511,811

Median for Physician Assistant: $4,110

Branded share of claims

22.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 73 $101,585
Ozempic Semaglutide Brand 49 $91,713
Eliquis Apixaban Brand 38 $48,169
Entresto Sacubitril/Valsartan Brand 33 $38,669
Mounjaro Tirzepatide Brand 23 $31,013
Jardiance Empagliflozin Brand 23 $28,390
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 17 $24,374
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $23,590
Praluent Pen Alirocumab Brand 17 $21,948
Farxiga Dapagliflozin Propanediol Brand 13 $20,760

The 10 drugs with the highest cost, of 91 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $107
$107 23 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $98
$98 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $97
$97 23 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $72
$72 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $67
$67 38 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

307 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record